Elanco's Zenrelia™, a JAK inhibitor for canine allergic dermatitis, receives FDA approval.

Elanco Animal Health has received FDA approval for Zenrelia™ (ilunocitinib), a once-daily oral treatment for allergic and atopic dermatitis in dogs over 12 months old. This JAK inhibitor effectively manages itching and inflammation, with visible results from the first dose. Zenrelia is more affordable than current treatments and minimizes rebound itch risks. Its launch aims to meet the demand for better dermatological options in canine health, benefiting millions of affected dogs.

September 19, 2024
11 Articles